XBiotech Inc. (NasdaqGS: XBIT)
Health Care · Biotechnology · US
$2.12
-7.42% today · -14.5% 1Y
XBiotech Inc. (NasdaqGS: XBIT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $64.63M and employs 87 people.
Over the last twelve months the share price has lost 14.5%, trading between 2.09 and 3.44.
Tweenvest scores XBiotech Inc. across four factors: quality 43/100, value 42/100. Its strongest factor is quality.
XBIT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $64.63M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.48
- Dividend yield
- —
- Beta (5Y)
- 0.80
- 52-week high
- $3.44
- 52-week low
- $2.09
- Avg volume (3M)
- —
- Shares outstanding
- 30.49M
- Employees
- 87
- Next earnings
- —
About XBiotech Inc.
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
- ISIN
- CA98400H1029
- Founded
- 2005
- Listed since
- Apr 15, 2015
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Lytix Biopharma ASAOB: LYTIX | $65.15M | Nkr8.00 | -2.44% |
| StemRIMTSE: 4599 | $65.11M | ¥164.00 | -6.29% |
| CORESTEMCHEMON Inc.KOSDAQ: A166480 | $64.85M | ₩1,949.00 | -16.71% |
| Spero Therapeutics, Inc.NasdaqGS: SPRO | $64.64M | $1.11 | -1.77% |
| iNtRON Biotechnology, Inc.KOSDAQ: A048530 | $64.53M | ₩2,785.00 | -2.11% |
| Fortress Biotech, Inc.NasdaqCM: FBIO | $64.37M | $1.93 | -3.02% |
| Oncolytics Biotech Inc.NasdaqCM: ONCY | $63.51M | $0.50 | -10.57% |
| EyeGene Inc.KOSDAQ: A185490 | $63.26M | ₩1,951.00 | +4.33% |
Figures last refreshed Oct 18, 2026.